) may compromise the ability to reduce dietary folate or synthetic folic acid to L methylfolate, also increasing Hcy levels. 5 A secondary pathway of Hcy metabolism is reduction via transulfuration (see Figure 1b) to form cysteine. Elevated levels of Hcy may increase the use of the transulfuration pathway, which is of concern due to the vascular toxicity of cysteine. In brain tissue, the enzyme necessary for transulfuration, cystathione-beta synthase (CBS), is minimally expressed. 5 Due to the low expression of CBS, Hcy metabolism in the CNS is largely dependent on re-methylation (see Figure 1c ). There are several acquired and genetic factors that can cause alterations in the metabolic pathways and lead to cognitive decline.
Acquired Factors
Hypomethylation related to hyperhomocysteinemia can result from a complex interaction of acquired and genetic factors. The most important acquired factor is a relative nutritional deficiency of methylfolate and methylcobalamin. Since 1998, the US Food and Drug Administration (FDA) has required that enriched grain products contain at least 140µg of folic acid per 100g. The effect of this low-level fortification on Hcy levels is not fully known.
Epidemiological studies 6, 7 have found an association between low cobalamin levels and elevated plasma Hcy. Importantly, there was no association between high Hcy and low cobalamin intake, suggesting that, in contrast to folate, failure to absorb cobalamin-rather than inadequate dietary consumption-was the main culprit. Individuals above 60 years of age are of particular concern because of age-related declines in vitamin absorption and extraction of cobalamin from protein, and age-related increases in autoimmunity against intrinsic factor or the gastric parietal cells that produce intrinsic factor. 8 Other factors that affect Hcy levels have received less attention. 
Genetic Factors
The methylenetetrahydrofolate reductase (MTHFR) 677 C→T genotype is a genetic factor controlling Hcy remethylation. This enzyme reduces 5,10-methylenetetrahydrofolate to L-methylfolate. L-methylfolate is needed to convert Hcy to methionine. Individuals with the C/T (heterozygous) or T/T (homozygous) polymorphism have higher concentrations of plasma Hcy. This is a common polymorphism, and may be present in as many of two-thirds of vascular dementia patients: 25.5% (T/T) homozygous, 40 .6% (C/T) heterozygous. 10 The MTHFR mutation produces modestly elevated plasma Hcy levels and a reduction in CNS L-methylfolate.
Consequences of Hyperhomocysteinemia
Abnormal levels of substrates and byproducts of Hcy metabolism can damage neurons and other components that are necessary for normal cognitive abilities. Mechanisms of hyperhomocysteinemiainduced cognitive dysfunction include oxidative stress and excitotoxicity resulting in accelerated apoptosis, augmentation of the toxicity of betaamyloid, interference with methylation reactions-potentially resulting in decreased synthesis of acetylcholine and increased phosphorylation of tau protein-and poly-ADP-ribose polymerase (PARP) activation, which results in a decreased ability to repair damaged DNA.
Oxidative Stress and Excitotoxicity
Toxic products of oxidative reactions 11 have been implicated in the pathogenesis of neurodegenerative diseases, including AD. In the extracellular space, Hcy is rapidly oxidized, producing reactive oxygen species.
12
Oxidative stress impairs the ability of the cobalamindependent enzyme methionine synthase to convert Hcy to methionine. 13 Furthermore, folate can also undergo irreversible oxidation, resulting in impaired conversion to L-methylfolate.
14

Excitotoxicity
It is important to note that homocysteine and its metabolites are potent agonists for N-methyl-D-aspartate (NMDA) receptors. 15 A potential mechanism of Hcy's role in excitotoxicity is its ability to mimic glutamate, a neurotransmitter. Elevated concentrations of glutamate, seen in individuals with cognitive impairment, induce overactivation of NMDA receptors and excitotoxicity-mediated cell death. Hcy may be attributed to the prolonged opening of NMDA ion channels, allowing excess calcium to enter the cell and resulting in a cascade of events culminating in apoptotic cell death. [16] [17] [18] There are multiple sites of Hcy binding-in addition to the glutamate NMDA receptor-that are responsible for adverse cell effects. 18 In fact, studies have shown that Hcy is toxic to cultured neurons at concentrations likely reached in the central nervous system (CNS) of hyperhomocysteinemic individuals after breakdown of the blood-brain barrier.
15,19
Increased Toxicity of Beta Amyloid
Elevated Hcy levels may compound a primary excitotoxic insult, 
Interference with Methylation Reactions
Synthesis of Acetylcholine
SAM is the universal source of one-carbon units for the synthesis of nucleic acids, phospholipids, proteins, polysaccharides, and biogenic amines. 19, 20 The generation of one-carbon units is dependent on Hcy metabolism. Inadequate L-methylfolate and B 12 levels can impair methylation of phospholipids, necessary for the production of phosphtidylcholine and ultimately, the synthesis of acetylcholine.
21-23
The Formation of Neurofibrillary Tangles
Deposited amyloid plaques and oxidized Hcy result in the generation of reactive oxygen species. The increased production of reactive oxygen PARP-mediated neuronal cell death is a major pathway for the death of neurons, and activation of this cascade may therefore be another important consequence of disturbed one-carbon metabolism. 25 If exacerbation of oxidative stress is the mechanism of Hcy-associated neurodegeneration, therapy with antioxidant compounds may also be necessary in addition to vitamin therapy to maximally protect neurons.
N-acetylcysteine (NAC) has been shown to significantly reduce the toxic oxidative effects of Hcy and beta amyloid. 26 NAC is also the precursor of glutathione, the most important antioxidant in the brain.
There is compelling evidence of an association between high serum levels of Hcy and AD. A deficiency of either vitamin B 12 or folate may cause elevated Hcy levels. Epidemiological studies found that AD is associated with relative deficiencies of vitamin B 12 and folate. [27] [28] [29] In addition, independent case-control studies have established an association between elevated serum Hcy levels and AD. [30] [31] [32] [33] The underlying metabolic pathways may be exploited to treat cognitive decline. methylcobalamin, and 600mg N-acetylcysteine. According to the FDA, a medical food is different both from a drug and from a food, and is defined as "a food that is formulated to be consumed orally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation." Medical foods are required when dietary management cannot achieve specific nutrient requirements. Further research is necessary to determine the exact priority this approach should be given in treatment algorithms for early memory loss.
Treatment of Cognitive Decline
The current paradigm of treatment for cognitive decline is such that intervention takes place relatively late in the course of disease. The use of medications currently approved by the FDA requires the establishment of a measurable cognitive deficit within strictly defined parameters. Progressive memory loss spans the spectrum from mild cognitive impairment as an entry point ranging to severe dementia at the extreme. Greater folate deficiency at the beginning Patients treated with folate showed a pilot study in which patients were randomly with serum folate levels <3ng/ml. Very mild of treatment was related to greater cognitive significant improvement in both memory assigned 15mg folic acid or placebo to moderate cognitive decline as assessed improvement over two months of treatment and attention efficiency. Degree of for 60 days. (Fioravanti, 1997 54 ) by GDS. MMSE scores 16-24. as measured by RMT. memory improvement was positively correlated with initial severity of folate deficiency. Severity of initial cognitive decline was unrelated to the degree of folate deficiency. Open-label trial using folinic acid 38 patients with conditions that included Patients treated with folinic acid experienced A relationship was observed between supplementation to study the relationship depression, asthenia, irritability, forgetfulness, an increase in folate levels (192 versus 347ng/ml) folate deficiency and decreases in learning, between folate deficiencies and lack of attention, and erythrocyte folate levels and improvements in Zung depression and memory, concentration, and vigilance; neuropsychiatric disturbances. <300ng/ml were matched with 100 BRC scores. deterioration of associative memory and (Rapin, 1988 55 ) age-matched controls (62±5 years). disruption of spatio-temporal organization had the greatest association with folate deficiency. After treatment patients reported that they 'feel better' and 'have more interest in life.' Open-label trial to determine the effect of 50 patients (age 81±7 years) were enrolled Depression symptoms were resolved in 50mg folinic acid given parenterally (on from a frequency study in which 75% of four patients; self-sufficiency was recovered in days one, 11, and 21) to patients with folate 1,000 elderly hospitalized patients were three dementia patients; and 32 patients deficiency and depression and/or dementia.
folate-deficient (serum folate <5ng/ml). showed improvement in either geriatric or (Brocker, 1986 56 ) psychiatric scores. opportunity to intervene has already been missed by the time frank disease has emerged. Therefore, primary prevention is geared more toward reducing the likelihood that existing risk factors lead to the expression of disease.
Moving into an even earlier stage in the life-cycle, primordial prevention is aimed at interfering with the emergence of risk factors in the first place. The appeal of early intervention in the primordial or primary stage is the preservation of existing function rather than simply the slowing of an inevitable decline. The MTHFR enzyme pathway and the reduction of Hcy appear to be one of the most promising targets for primordial and primary prevention of cognitive decline, not to mention rescue or salvage therapy for patients already suffering from diminished cognitive abilities.
Folate supplementation has been shown to be effective in treating agerelated cognitive decline or dementia, as demonstrated in the nine studies that are summarized in Table 1 . 48-56 ■ 
